Business Of Biotech cover image

Reprogramming Human Cells With bit.bio's Mark Kotter, M.D.

Business Of Biotech

00:00

Tackling Common Indications in Regenerative Medicine

This chapter explores how Bitbio is shifting focus towards common indications in regenerative medicine, aiming to de-risk clinical trials and democratize access to therapies through large-scale cell production. The discussion covers challenges in the cell therapy space, the company's progress in cellular persistence and manufacturing strategies, as well as partnerships with top pharma companies for funding and development.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app